Swiss drug maker Roche says sales dip

Swiss drug maker Roche says sales dip

PanARMENIAN.Net - Swiss drug maker Roche Holding AG reported Thursday, April 12, that group sales dipped one percent to 11.03 billion Swiss francs ($12.05 billion) in the first quarter, while hinting that it might be prepared to raise its offer for U.S. diagnostics firm Illumina Inc., The Associated Press reported.

Excluding the effect of the strong Swiss currency, group sales rose two percent compared to the same period last year.

Analysts had expected slightly higher sales of around 11.58 billion francs.

"We remain on track to achieve our targets for the full year," Roche chief executive Severin Schwan said in a statement citing forthcoming new drugs to combat skin cancer and other diseases.

Sales in the United States grew six percent in the first quarter, led by hepatitis C medicine Pegasys and cancer drug Rituxan - known as MabThera outside the U.S. and Canada. Sales in Western Europe fell four percent partly due to cutbacks in government-funded health programs. Roche, which reports earnings only every six months, said group sales are expected to grow at low to mid-single-digit rates for the full year 2012.

Addressing the monthslong effort to take over California-based Illumina, which specializes in gene sequencing to analyze patients' DNA, the Roche CEO indicated that a higher bid might still be possible.

On Wednesday, Roche sent a letter to Illumina shareholders ahead of the company's annual meeting in New York on April 18.

In the letter, Roche warned that Illumina's financial success was far less certain than the California company's board made out when it described itself as "the Apple of the genomics business."

"Unlike at Apple stores, crowd control of eager buyers has not been a problem for Illumina and not even Illumina has projected any surge in revenues from its products in any specific foreseeable time period," Roche said.

 Top stories
“A 10% credit portfolio upsurge was registered in the first 7 months of 2014, with the bank planning to bring the figure to $550M,” Sahakyan said.
The revised figures are based on the forecast for the Russian economy to contract by 1.0% in 2014, followed by stagnation in 2015.
“The key powers in the region are unlikely to favor an outbreak of conflict on their southern and eastern flanks,” the report says.
The Commission aims to compensate producers who decide to not harvest some of their goods or give products away for free.
Partner news